OncoMatch/Clinical Trials/NCT06244771
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Official title: An Open-Label, Phase 1/2 Dose Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 Monotherapy and in Combination With Pembrolizumab in Participants With KRAS G12C Mutated Advanced Solid Tumors
Is NCT06244771 recruiting? Yes, currently enrolling (Oct 2026). This Phase 1/2 trial studies FMC-376 for advanced solid tumors with kras g12c mutations.
Treatment: FMC-376 — The goal of this clinical trial is to evaluate FMC-376 monotherapy and in combination with pembrolizumab in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants with advanced solid tumors will be evaluated.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: KRAS g12c
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
adequate hematological function
Kidney function
adequate renal function
Liver function
adequate hepatic function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California San Diego (UC San Diego) Health - Jacobs Medical Center - Moores Cancer Center · La Jolla, California
- University of California Irvine (UCI) - Chao Family Comprehensive Cancer Center · Orange, California
- University of California San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center · San Francisco, California
- Florida Cancer Specialists and Research Institute · Lake Mary, Florida
- Northwest Cancer Centers · Dyer, Indiana
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06244771 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require KRAS?
Yes, KRAS g12c is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages